or Try an Advanced Search...

    Lupus Nephritis Stocks List

    Symbol Grade Name % Change
    AUPH C Aurinia Pharmaceuticals Inc 2.06
    BIIB F Biogen Idec Inc. 1.10
    KYTX F Kyverna Therapeutics, Inc. -1.21
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Lupus Autoimmune Disease Biopharmaceutical Immunosuppressants Medicine Multiple Sclerosis Nephritis Alzheimer's Disease Autoimmune Disorders Autoimmunity Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia

    Related ETFs - A few ETFs which own one or more of the above listed Lupus Nephritis stocks.

    Symbol Grade Name Weight
    BIS B ProShares UltraShort Nasdaq Biotechnology 6.12
    PBE D PowerShares Dynamic Biotech & Genome 4.21
    BBH D Market Vectors Biotech ETF 3.86
    MNTL D Tema Neuroscience and Mental Health ETF 3.57
    BBP C BioShares Biotechnology Products Fund 3.34
    View all Lupus Nephritis ETFs...
    Compare ETFs
    Compare BBH to MNTL Compare MNTL to BBP Compare PBE to MNTL

        Lupus Nephritis Stocks Recent News

        Date Stock Title
        Nov 20 BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
        Nov 20 BIIB Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 BIIB Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
        Nov 19 BIIB Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
        Nov 18 AUPH Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
        Nov 18 BIIB Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
        Nov 18 BIIB Needham downgrades Biogen on slow growth of Alzheimer's drug
        Nov 18 BIIB Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
        Nov 18 BIIB Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
        Nov 18 BIIB Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
        Nov 17 KYTX institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop
        Nov 15 BIIB Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
        Nov 15 AUPH Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
        Nov 14 BIIB European committee takes a second look at Alzheimer's drug and now says it should be approved
        Nov 14 BIIB 5 Healthcare Stocks to Buy in a Beaten-Up Sector
        Nov 14 BIIB Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
        Nov 14 KYTX Kyverna Therapeutics GAAP EPS of -$0.80
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Lupus Autoimmune Disease Biopharmaceutical Immunosuppressants Medicine Multiple Sclerosis Nephritis Alzheimer's Disease Autoimmune Disorders Autoimmunity Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia
        Lupus Nephritis

        Lupus nephritis (also known as SLE nephritis) is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), an autoimmune disease. It is a type of glomerulonephritis in which the glomeruli become inflamed. As the result of SLE, the cause of glomerulonephritis is said to be secondary and has a different pattern and outcome from conditions with a primary cause originating in the kidney.

        More about Lupus Nephritis
        Browse All Tags